Next Biomedical Co.,Ltd. (KOSDAQ:389650)

Next Biomedical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	4,070	4,950	3,902	3,014	22,016	6,740
Short-Term Investments	1,600	20,766	10,388	11,783	-	-
Trading Asset Securities	25,675	15,892	-	-	-	-
Cash & Short-Term Investments	31,345	41,609	14,290	14,797	22,016	6,740
Cash Growth	129.67%	191.17%	-3.43%	-32.79%	226.66%	-39.94%
Accounts Receivable	2,324	1,845	918.64	314.3	118.67	104.03
Other Receivables	93.04	321.39	214.28	170.84	86.52	6.55
Receivables	2,418	2,167	1,133	485.15	205.19	110.58
Inventory	2,548	2,581	2,169	1,940	1,313	1,973
Prepaid Expenses	338.63	190.08	155.85	207.32	138.44	186.68
Other Current Assets	221.58	341.35	220.7	90.8	65.69	304.12
Total Current Assets	36,871	46,888	17,968	17,521	23,739	9,315
Property, Plant & Equipment	13,349	11,270	11,428	11,735	11,918	11,860
Long-Term Investments	8,168	-	-	2,637	3,737	3,088
Other Intangible Assets	316.88	344.38	217.63	222.19	288.71	288.99
Long-Term Accounts Receivable	-0	-0	-0	-0	-0	0
Other Long-Term Assets	691.25	342.75	29.48	21.35	37.51	38.82
Total Assets	59,396	58,844	29,643	32,136	39,720	24,591
Accounts Payable	183.54	13.37	58.16	45.02	4.1	9.19
Accrued Expenses	162.3	126.23	121.14	106.93	96.48	91.11
Short-Term Debt	5,600	5,600	5,600	5,600	5,600	4,430
Current Portion of Long-Term Debt	4,609	4,539	4,897	4,800	5,200	5,600
Current Portion of Leases	20.86	26.37	41.51	35.6	32.24	37.92
Other Current Liabilities	1,429	1,579	714.37	452.97	2,115	28,503
Total Current Liabilities	12,005	11,884	11,433	11,041	13,048	38,671
Long-Term Debt	1,304	763.5	933.54	500	20,873	3,456
Long-Term Leases	11.9	20.58	46.9	81.63	46.55	39.96
Other Long-Term Liabilities	244.17	235.35	218.84	368.8	284.7	18,999
Total Liabilities	14,439	13,653	13,191	12,462	34,636	61,457
Common Stock	4,063	4,043	3,174	3,110	3,105	713.29
Additional Paid-In Capital	107,938	107,234	61,632	60,679	60,603	2,499
Retained Earnings	-71,620	-70,181	-72,984	-65,367	-59,673	-43,043
Comprehensive Income & Other	4,575	4,095	2,277	1,324	1,049	724.57
Total Common Equity	44,957	45,191	-5,901	-253.84	5,084	-39,106
Shareholders' Equity	44,957	45,191	16,452	19,674	5,084	-36,866
Total Liabilities & Equity	59,396	58,844	29,643	32,136	39,720	24,591
Total Debt	11,546	10,949	11,519	11,017	31,751	13,564
Net Cash (Debt)	19,799	30,659	2,771	3,780	-9,735	-6,824
Net Cash Growth	784.34%	1006.61%	-26.70%	-	-	-
Net Cash Per Share	2429.95	4146.00	441.28	608.67	-2011.96	-1594.48
Filing Date Shares Outstanding	8.13	8.09	6.28	6.21	4.84	4.28
Total Common Shares Outstanding	8.13	8.09	6.28	6.21	4.84	4.28
Working Capital	24,866	35,004	6,536	6,480	10,691	-29,357
Book Value Per Share	5532.48	5588.37	-939.89	-40.88	1050.64	-9136.87
Tangible Book Value	44,640	44,847	-6,119	-476.03	4,795	-39,395
Tangible Book Value Per Share	5493.49	5545.78	-974.55	-76.65	990.97	-9204.39
Land	5,618	5,277	5,277	5,277	5,277	5,385
Buildings	6,737	5,786	5,786	5,786	5,786	5,044
Machinery	1,509	1,598	1,430	1,397	1,504	1,338
Construction In Progress	1,061	99.29	119.06	150.11	188.87	660.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.